INZY
Closed
Inozyme Pharma inc
4.
0 (0.00%)
Last Update: 30 Jun 2025 23:19:00
Yesterday: 3.99
Day's Range: 3.99 - 4.
Send
sign up or login to leave a comment!
When Written:
5.42
Inozyme Pharma Inc is a biopharmaceutical company focused on developing novel therapies for the treatment of rare diseases related to abnormal mineralization. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Inozyme's lead product candidate, INZ-701, is an enzyme replacement therapy designed to treat a rare genetic disorder called hypophosphatasia (HPP), which causes abnormal mineralization of bones and teeth. The company is also developing other product candidates for the treatment of rare diseases related to abnormal mineralization.
Inozyme is led by a team of experienced biopharmaceutical executives and has collaborations with academic institutions and pharmaceutical companies. The company went public in August 2020 and is listed on the NASDAQ under the ticker symbol "INZY".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Inozyme's lead product candidate, INZ-701, is an enzyme replacement therapy designed to treat a rare genetic disorder called hypophosphatasia (HPP), which causes abnormal mineralization of bones and teeth. The company is also developing other product candidates for the treatment of rare diseases related to abnormal mineralization.
Inozyme is led by a team of experienced biopharmaceutical executives and has collaborations with academic institutions and pharmaceutical companies. The company went public in August 2020 and is listed on the NASDAQ under the ticker symbol "INZY".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








